In particular, regarding human epidermal growth factor receptor 2 positive (HER-2+) eBC, the NeoSphere randomized phase 2 trial showed some benefit in terms of pCR in operable, locally advanced, and inflammatory BC when treated with four neoadjuvant cycles of docetaxel/pertuzumab/trastuzumab and also demonstrated favorable progression-free survival outcomes at the 5-year follow-up [10]. Here, ERBB2 is linked to breast cancer.